BACKGROUND: Pharmacotherapy studies involving buprenorphine have rarely been conducted with U.S. community corrections populations. This is one of the first reports of buprenorphine treatment outcomes of adult opioid-dependent probationers and parolees. METHODS: This longitudinal study examined the 3-month treatment outcomes for a sample of probation and parole clients (N = 64) who received community-based buprenorphine treatment. RESULTS: Approximately two thirds of the sample (67%) were still in treatment at 3 months post baseline. Furthermore, there was a significant decline in the number of self-reported heroin use days and crime days from baseline to 3 months post baseline. Although there was not a significant reduction in reincarcerations, there was no evidence that they had increased. CONCLUSIONS: Given that buprenorphine is approved by the Food and Drug Administration (FDA) as a safe, effective treatment for opioid use disorders, individuals on parole or probation should have the opportunity to benefit from it through community-based programs.
BACKGROUND: Pharmacotherapy studies involving buprenorphine have rarely been conducted with U.S. community corrections populations. This is one of the first reports of buprenorphine treatment outcomes of adult opioid-dependent probationers and parolees. METHODS: This longitudinal study examined the 3-month treatment outcomes for a sample of probation and parole clients (N = 64) who received community-based buprenorphine treatment. RESULTS: Approximately two thirds of the sample (67%) were still in treatment at 3 months post baseline. Furthermore, there was a significant decline in the number of self-reported heroin use days and crime days from baseline to 3 months post baseline. Although there was not a significant reduction in reincarcerations, there was no evidence that they had increased. CONCLUSIONS: Given that buprenorphine is approved by the Food and Drug Administration (FDA) as a safe, effective treatment for opioid use disorders, individuals on parole or probation should have the opportunity to benefit from it through community-based programs.
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Karen L Cropsey; Peter S Lane; Galen J Hale; Dorothy O Jackson; C Brendan Clark; Karen S Ingersoll; M Aminul Islam; Maxine L Stitzer Journal: Drug Alcohol Depend Date: 2011-07-23 Impact factor: 4.492
Authors: Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum Journal: Drug Alcohol Depend Date: 2008-10-18 Impact factor: 4.492
Authors: Shannon Gwin Mitchell; Jennifer Willet; Laura B Monico; Amy James; Danielle S Rudes; Jill Viglione; Robert P Schwartz; Michael S Gordon; Peter D Friedmann Journal: Subst Abus Date: 2016 Impact factor: 3.716
Authors: Robert P Schwartz; Mary M Mitchell; Kevin E O'Grady; Sharon M Kelly; Jan Gryczynski; Shannon Gwin Mitchell; Michael S Gordon; Jerome H Jaffe Journal: Int Rev Psychiatry Date: 2018-12-06
Authors: Sean M Murphy; Daniel Polsky; Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Richard J Bonnie; Michael Gordon; Donna T Chen; Tamara Y Boney; Charles P O'Brien Journal: Addiction Date: 2017-04-12 Impact factor: 6.526
Authors: Peter D Friedmann; Donna Wilson; Edward V Nunes; Randall Hoskinson; Joshua D Lee; Michael Gordon; Sean M Murphy; Richard J Bonnie; Donna T Chen; Tamara Y Boney; Charles P O'Brien Journal: J Subst Abuse Treat Date: 2017-02-22
Authors: Joshua D Lee; Peter D Friedmann; Tamara Y Boney; Randall A Hoskinson; Ryan McDonald; Michael Gordon; Marc Fishman; Donna T Chen; Richard J Bonnie; Timothy W Kinlock; Edward V Nunes; James W Cornish; Charles P O'Brien Journal: Contemp Clin Trials Date: 2015-01-17 Impact factor: 2.226
Authors: Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Tamara Y Boney; Randall A Hoskinson; Donna Wilson; Ryan McDonald; John Rotrosen; Marc N Gourevitch; Michael Gordon; Marc Fishman; Donna T Chen; Richard J Bonnie; James W Cornish; Sean M Murphy; Charles P O'Brien Journal: N Engl J Med Date: 2016-03-31 Impact factor: 91.245
Authors: Rosemarie A Martin; L A R Stein; Damaris J Rohsenow; Steven Belenko; Linda E Hurley; Jennifer G Clarke; Lauren Brinkley-Rubinstein Journal: J Subst Abuse Treat Date: 2021-03-12
Authors: Sean M Murphy; Philip J Jeng; Sabrina A Poole; Ali Jalali; Frank J Vocci; Michael S Gordon; George E Woody; Daniel Polsky Journal: Addict Sci Clin Pract Date: 2020-04-22